{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:44:13Z","timestamp":1791024253211,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,4,1]]},"DOI":"10.1097\/qai.0b013e318033ffa1","type":"journal-article","created":{"date-parts":[[2007,2,27]],"date-time":"2007-02-27T14:55:10Z","timestamp":1172588110000},"page":"456-462","source":"Crossref","is-referenced-by-count":65,"title":["Clinical Toxicity of Highly Active Antiretroviral Therapy in a Home-Based AIDS Care Program in Rural Uganda"],"prefix":"10.1097","volume":"44","author":[{"given":"Fatu","family":"Forna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl A","family":"Liechty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Solberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Asiimwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willy","family":"Were","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mermin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prosper","family":"Behumbiize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Weidle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210131","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJM199604183341602","article-title":"Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.","volume":"334","author":"Collier","year":"1996","journal-title":"N Engl J Med"},{"key":"R2-13-20210131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.","volume":"338","author":"Palella","year":"1998","journal-title":"N Engl J Med"},{"key":"R3-13-20210131","first-page":"659","article-title":"Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.","volume":"160","author":"Hogg","year":"1999","journal-title":"CMAJ"},{"key":"R4-13-20210131","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"R8-13-20210131","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1086\/426076","article-title":"Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV Outpatient Study Cohort.","volume":"40","author":"Lichtenstein","year":"2005","journal-title":"Clin Infect Dis"},{"key":"R9-13-20210131","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study.","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R10-13-20210131","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"R11-13-20210131","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/00002030-200501280-00011","article-title":"Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.","volume":"19","author":"Ananworanich","year":"2005","journal-title":"AIDS"},{"key":"R13-13-20210131","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/01.qai.0000159668.80207.5b","article-title":"Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana.","volume":"40","author":"Wester","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R14-13-20210131","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/01.qai.0000159516.39982.1b","article-title":"Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.","volume":"40","author":"Idigbe","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-13-20210131","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-3156.2005.01409.x","article-title":"Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.","volume":"10","author":"van Oosterhout","year":"2005","journal-title":"Trop Med Int Health"},{"key":"R16-13-20210131","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/00002030-200207050-00008","article-title":"The Senegalese governments highly active antiretroviral therapy initiative: an 18-month follow-up study.","volume":"16","author":"Laurent","year":"2002","journal-title":"AIDS"},{"issue":"Suppl","key":"R17-13-20210131","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/00002030-200317003-00002","article-title":"Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote dIvoire.","volume":"17","author":"Djomand","year":"2003","journal-title":"AIDS"},{"key":"R18-13-20210131","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1089\/08892220260387922","article-title":"Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients.","volume":"18","author":"Kebba","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R19-13-20210131","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1097\/00002030-200309050-00023","article-title":"Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres.","volume":"17","author":"Tassie","year":"2003","journal-title":"AIDS"},{"key":"R20-13-20210131","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(04)16586-0","article-title":"Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1 infected adults in Cameroon: open-label multicentre trial.","volume":"364","author":"Laurent","year":"2004","journal-title":"Lancet"},{"key":"R21-13-20210131","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00002030-200404090-00006","article-title":"Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa.","volume":"18","author":"Coetzee","year":"2004","journal-title":"AIDS"},{"key":"R22-13-20210131","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1086\/499044","article-title":"Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.","volume":"42","author":"Spacek","year":"2006","journal-title":"Clin Infect Dis"},{"key":"R23-13-20210131","first-page":"48","article-title":"Access to and early outcomes of a public South African adult antiretroviral clinic.","volume":"19","author":"Hudspeth","year":"2004","journal-title":"South African Journal of Epidemiology and Infection"},{"key":"R24-13-20210131","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/00126334-200408010-00006","article-title":"A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.","volume":"36","author":"Jack","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-13-20210131","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa051908","article-title":"Antiretroviral therapy in a thousand patients with AIDS in Haiti.","volume":"353","author":"Severe","year":"2005","journal-title":"N Engl J Med"},{"key":"R27-13-20210131","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0140-6736(01)06413-3","article-title":"Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.","volume":"358","author":"Fellay","year":"2001","journal-title":"Lancet"},{"key":"R28-13-20210131","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00042560-200003010-00004","article-title":"Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study.","volume":"23","author":"Bonfanti","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R29-13-20210131","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00002030-200003310-00005","article-title":"Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients.","volume":"14","author":"dArminio MA, Lepri","year":"2000","journal-title":"AIDS"},{"key":"R30-13-20210131","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/clinids\/19.6.1076","article-title":"Rates and risk factors for adverse events associated with didanosine in the expanded access program.","volume":"19","author":"Schindzielorz","year":"1994","journal-title":"Clin Infect Dis"},{"key":"R31-13-20210131","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1056\/NEJMoa030265","article-title":"Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.","volume":"349","author":"Shafer","year":"2003","journal-title":"N Engl J Med"},{"key":"R32-13-20210131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"R33-13-20210131","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1001\/archneur.1988.00520330023005","article-title":"Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey.","volume":"45","author":"So","year":"1988","journal-title":"Arch Neurol"},{"key":"R34-13-20210131","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1212\/WNL.38.5.794","article-title":"Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex.","volume":"38","author":"Cornblath","year":"1988","journal-title":"Neurology"},{"key":"R35-13-20210131","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/infdis\/167.1.21","article-title":"2,3-didehydro-3-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex:a phase I trial.","volume":"167","author":"Browne","year":"1993","journal-title":"J Infect Dis"},{"issue":"Suppl","key":"R36-13-20210131","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/infdis\/171.Supplement_2.S113","article-title":"Biologic effects and safety of stavudine: overview of phase I and II clinical trials.","volume":"171","author":"Skowron","year":"1995","journal-title":"J Infect Dis"},{"key":"R37-13-20210131","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","article-title":"Adverse effects of antiretroviral therapy.","volume":"356","author":"Carr","year":"2000","journal-title":"Lancet"},{"key":"R38-13-20210131","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00002018-199819060-00005","article-title":"Peripheral neuropathy with nucleoside antiretrovirals: risk factors, incidence and management.","volume":"6","author":"Moyle","year":"1998","journal-title":"Drug Saf"},{"key":"R40-13-20210131","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(04)17225-5","article-title":"Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.","volume":"364","author":"Mermin","year":"2004","journal-title":"Lancet"},{"key":"R41-13-20210131","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.qai.0000245879.36015.54","article-title":"Estimating HIV incidence in voluntary counseling and testing clients in Uganda (1992-2003).","volume":"44","author":"Baryarama","year":"2007","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00126334-200704010-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:18:57Z","timestamp":1618039137000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-200704010-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e318033ffa1","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4,1]]}}}